IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Yoshiko MINAKUCHI et al.			
Application No. 10/583,277	Confirmation No. 2615		
Filed: June 16, 2006	Art Unit: 1633		
For: NOVEL METHOD OF NUCLEIC ACID TRANSFER	Examiner: Q. Nguyen		

INFORMATION DISCLOSURE STATEMENT

MS RCE Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Sir:

H.

Applicants hereby submit an Information Disclosure Statement for consideration by the Examiner.

I. <u>LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION</u>

The patents, publications, or other information submitted for consideration by the Office are listed on the PTO-SB08.

		0.11110			
	a.	Copies of foreign patent documents, non-patent literature and other information.			
П	b.	REFERENCES PREVIOUSLY CITED OR SUBMITTED; Copies of an			

information not provided can be found in one or more of the following applications which has

been relied upon for an earlier filing date under 35 U.S.C. § 120:

COPIES

III. CONCISE EXPLANATION OF THE RELEVANCE
a. NON-ENGLISH LANGUAGE DOCUMENTS: A concise explanation of the
relevance of all non-English language patents, publications, or other information listed is as
follows: English abstracts are provided for JP 09-099052, JP 09-071542, JP 2001-335512, and
WO 03/000297.
COMMUNICATION: An English language version of the search report or Foreign Patent
Office communication that indicates the degree of relevance is attached: Supplemental European
Search Report – EP 04807517 – dated November 23, 2006.
c. OTHER: The following additional information is provided.
IV. STATEMENT UNDER 37 C.F.R. § 1.97(e)
The undersigned hereby states that:
a. Each item of information contained in the IDS was first cited in any communication from a foreign patent office in a counterpart foreign application not more than 30
days prior to the filing of this IDS. This statement does not relate to English language
counterparts not listed in a communication from the foreign patent office. Such English language
counterparts are provided to aid the Examiner's consideration of non-English items first cited in
the communication from the foreign patent office; or
□ b. Each item of information contained in the IDS was first cited in any
communication from a foreign patent office in a counterpart foreign application not more than
three months prior to the filing of this IDS. This statement does not relate to English language
counterparts not listed in a communication from the foreign patent office. Such English
language counterparts are provided to aid the Examiner's consideration of non-English items
Bands segmentaring are brestaged to aid the examiner a consideration of non-existing items

first cited in the communication from the foreign patent office; or

2 DRN/II

No item of information contained in the IDS was cited in a communication from
foreign patent office in a counterpart foreign application, and, to the knowledge of the person
signing the certification after making reasonable inquiry, no item of IDS was known to an
individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of th
IDS.
d. Some of the items of information in the IDS were cited in a communication from
a foreign patent office. Such items were first cited in a communication from a foreign patent
office in a counterpart foreign application not more than three months prior to the filing of thi
IDS. This statement does not relate to English language counterparts not listed in
communication from the foreign patent office. Such English language counterparts are provided
to aid the Examiner's consideration of non-English items first cited in the communication from
the foreign patent office. As to the remaining items of information, to the knowledge of the
person signing the certification after making reasonable inquiry, such remaining items were no
known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the
filing of this statement.
V. FEES
a. This Information Disclosure Statement is being filed concurrently with the filing
of a new patent application or Request for Continued Examination. No fee is required.
b. This Information Disclosure Statement is being filed within three months of the
filing date of an application. No fee is required.
. This Information Disclosure Statement is being filed before the mailing date of a
first Action on the merits. No fee is required. If a first Office Action on the merits has issued

please consider this IDS under 37 C.F.R. § 1.97(c) and see the statement under 37 C.F.R. §

1.97(e) above. If no statement has been made, charge our deposit account for the required fee.

3 DRN/II

	d.	This Information Disclosure S	tatement is being filed before the mailing date of a
Final	Office	Action or before the mailing	date of a Notice of Allowance (see 37 C.F.R. §
1.97(c	(1)).		
		No statement. The fee as requior	ired by 37 C.F.R. § 1.17(p) is provided.
		See the above statement. No fe	ee is required.
		Action or <u>after</u> the mailing date	Statement is being filed <u>after</u> the mailing date of a of a Notice of Allowance (see 37 C.F.R. § 1.97(d)), by 37 C.F.R. § 1.17(p) is provided.
VI.		MENT OF FEES	
		The required fee is listed on the	e attached Fee Transmittal.
	\boxtimes	No fee is required.	
	etermin er this	ed that this IDS has been filed	cerning this IDS, please contact the undersigned. If under the wrong rule, the USPTO is requested to charge the appropriate fee to Deposit Account No.
		mber 13, 2010	Respectfully submitted,
Attach ⊠	ments; PTO/S	3B/08	By
X X	Docum	nents n Search Report	
\wedge	roreig	n Search Kebort	

4 DRN/II